GSK plc vs Boston Beer Company Inc — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while Boston Beer Company Inc trades at $177.2 (market cap $1.86B). The key difference: GSK plc is far larger — about 55.2× Boston Beer Company Inc's market cap, and GSK plc pays a 3.57% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| GSK | SAM | |
|---|---|---|
Market Cap | $102.60B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $260.05 |
52-Week Low | $38.22 | $161.08 |
Enterprise Value | $123.04B | $1.63B |
Dividend Yield | 3.57% | — |
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →